Cybin Inc. (NASDAQ:HELP - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday following a dissappointing earnings announcement. The stock has a 200-day moving average of $7.81 and traded as low as $6.90. Cybin shares last traded at $7.67, with a volume of 12,808,773 shares.
The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.74).
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on HELP shares. Wall Street Zen downgraded shares of Cybin from a "sell" rating to a "strong sell" rating in a research note on Saturday, November 7th. Wells Fargo & Company increased their price objective on shares of Cybin from $16.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday, October 22nd. Barclays assumed coverage on shares of Cybin in a report on Friday, September 18th. They set an "overweight" rating and a $35.00 price objective for the company. Finally, TD Cowen raised their price objective on shares of Cybin from $8.00 to $62.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Six analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $47.33.
View Our Latest Analysis on HELP
Insider Buying and Selling
In related news, CFO Greg Cavers bought 3,000 shares of the company's stock in a transaction dated Tuesday, September 29th. The stock was acquired at an average cost of $12.91 per share, with a total value of $38,730.00. Following the acquisition, the chief financial officer owned 3,000 shares in the company, valued at approximately $38,730. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul Glavine bought 100,000 shares of the business's stock in a transaction that occurred on Tuesday, September 8th. The shares were bought at an average price of $12.47 per share, with a total value of $1,247,000.00. Following the transaction, the insider directly owned 4,271,252 shares in the company, valued at $53,262,512.44. This trade represents a 2.40% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 688,000 shares of company stock valued at $8,422,830. 15.00% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in HELP. AXQ Capital LP acquired a new stake in shares of Cybin in the 2nd quarter valued at $75,000. Farther Finance Advisors LLC grew its holdings in shares of Cybin by 927.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company's stock worth $280,000 after purchasing an additional 20,597 shares during the last quarter. State Street Corp bought a new stake in shares of Cybin in the 3rd quarter worth about $363,000. WealthPlan Investment Management LLC acquired a new stake in shares of Cybin during the 3rd quarter worth about $1,272,000. Finally, ACT Capital Partners L.P. acquired a new position in Cybin in the third quarter valued at about $1,659,000. 17.94% of the stock is owned by institutional investors.
Cybin Stock Down 13.5%
The stock has a market capitalization of $612.14 million, a price-to-earnings ratio of -2.54 and a beta of 0.64. The stock's 50-day simple moving average is $11.15 and its 200 day simple moving average is $7.81.
About Cybin
(
Get Free Report)
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company's pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.